Amiodarone-Induced Thyroid Disorders

Definition

Amiodarone-induced thyroid disorders (AITD) encompass a spectrum of thyroid dysfunction occurring in ~20% of amiodarone-treated patients, arising from both iodine overload and direct cytotoxic mechanisms. They manifest as hypothyroidism (AIH) or thyrotoxicosis (AIT), with AIT further classified into Type 1 (iodine-driven overproduction), Type 2 (destructive thyroiditis), or mixed. Neither form is dose-dependent. Thyroid dysfunction can appear at any time during or up to 16 months after amiodarone therapy.

Key Concepts

Epidemiology

• Overall incidence 2–24%; hypothyroidism more common than thyrotoxicosis
• AIH: 10–20% onset within 3 months; 5–10% onset >1 year; median 183 days
  • Risk factors: female sex (F:M 1.5:1; 19.2% women vs 13.3% men), underlying Hashimoto thyroiditis, iodine-replete areas (22% incidence)
• AIT: incidence 5–10%; median 720 days to onset
  • Risk factors: male sex (3.9–8.5% vs 0.4% women), iodine-deficient areas (10%)
  • Type 2 more prevalent in iodine-sufficient areas
• AIT carries 23% ICU mortality when complicated by thyroid storm
• sources/amiodarone-thyroid-jcem-2021, rating: high

Iodine Overload as Mechanism

• Each 200 mg amiodarone tablet contains 75 mg iodine; ~7 mg free iodine released — 23–47× the normal daily requirement of 0.15–0.30 mg
• Wolff-Chaikoff effect: iodine excess inhibits thyroid organification → ↓ T3/T4 → ↑ TSH. Normal glands "escape"; failure to escape = AIH
• Jod-Basedow phenomenon: autonomous thyroid tissue (multinodular goiter, Graves') responds to excess iodine with unregulated hormone overproduction = Type 1 AIT
• sources/amiodarone-thyroid-jcem-2021, rating: high

Non-Iodine Direct Cytotoxic Mechanisms

• Amiodarone inhibits peripheral deiodinases → ↓ T4→T3 conversion → ↓ serum T3, ↑ reverse T3 (rT3) — even in euthyroid patients
• Amiodarone/desethylamiodarone inhibits T3 nuclear receptor binding → ↓ thyroid hormone-regulated gene expression
• Direct apoptotic cytotoxicity on thyroid follicular cells → destructive thyroiditis = basis of Type 2 AIT
• Result in euthyroid patients: transient ↑ TSH/FT4/rT3 in first month of therapy → normalises 3–6 months; T3 remains persistently low
• sources/amiodarone-thyroid-jcem-2021, rating: high; sources/amiodarone-cvdrug-2020, rating: high

AIT Type 1 — Iodine-Induced Autonomous Overproduction

• Predisposed thyroid: autonomous function (multinodular goiter, Graves' disease); iodine-deficient geographical background
• Onset: typically 2–6 months post-initiation
• Biochemistry: suppressed TSH, elevated FT4, normal/elevated FT3; TSH receptor antibodies elevated in Graves'; may show underlying goiter on US
• Treatment:
  • Methimazole 40–60 mg/day (preferred over PTU for lower hepatotoxicity); may escalate to 120 mg/day
  • Potassium/sodium perchlorate adjunct (not available in USA)
  • Lithium adjunct (limited by toxicity)
  • Methimazole failure at 3–4 weeks → suspect mixed type
  • If amiodarone withdrawn: continue methimazole until urinary iodine normalises (6–18 months); 75% risk re-AIT if amiodarone reintroduced
• sources/amiodarone-thyroid-jcem-2021, rating: high

AIT Type 2 — Destructive Thyroiditis

• Predisposed thyroid: previously normal or near-normal gland
• Onset: much later — median 27–32 months; can occur 7–16 months after amiodarone withdrawal (7% of cases); 23% develop AIT only after withdrawal
• Biochemistry: suppressed TSH, elevated FT4, normal/elevated FT3; negative TSH receptor antibodies; presence of anti-TPO/TG antibodies does NOT exclude Type 2
• Natural history: resembles subacute thyroiditis — thyrotoxicosis → euthyroidism → hypothyroidism (17% permanently hypothyroid vs 5% in non-amiodarone subacute thyroiditis)
• Treatment:
  • Prednisone 30–40 mg/day × 2–4 weeks, then taper over 2–3 months
  • Mild thyrotoxicosis in stable cardiac patient: watchful waiting acceptable
  • Failed prednisone → combined IV methylprednisolone + oral (small case series only)
  • FT3/TT3 normalisation expected within average 8 days on prednisolone
  • Amiodarone continuation feasible (self-limited process); recurrence rate 6–75%
  • 16% permanently hypothyroid after glucocorticoid course completes
• sources/amiodarone-thyroid-jcem-2021, rating: high

Mixed Type 1/Type 2 AIT

• Suspected after failure of monotherapy (prednisone or methimazole alone)
• Treat with both simultaneously: methimazole 40 mg/day + prednisone 40 mg/day
• If FT3/TT3 declines >50%: Type 2 most likely → taper thionamide
• Once response achieved: taper one agent; no response → thyroidectomy
• In critical/haemodynamically unstable patients: do not wait for diagnostic clarity — initiate combined therapy empirically
• sources/amiodarone-thyroid-jcem-2021, rating: high

Amiodarone-Induced Hypothyroidism (AIH)

• Due to Wolff-Chaikoff failure ± underlying Hashimoto thyroiditis
• 60% of AIH is transient — resolves 2–4 months after amiodarone cessation
• Treatment: levothyroxine at appropriate starting dose; increase gradually to avoid precipitating arrhythmias
• Amiodarone may be continued for life-threatening arrhythmias
• Monitoring: TSH + FT4 every 3 months
• sources/amiodarone-thyroid-jcem-2021, rating: high; sources/amiodarone-cvdrug-2020, rating: high

Diagnostic Differentiation Type 1 vs Type 2

• Ultrasound + colour Doppler (most practical):
  • Type 1: structural thyroid abnormality; normal or increased vascularity
  • Type 2: normal/reduced vascularity — key discriminating finding even if small nodular goiter present (iodine-deficient areas)
• MIBI scintigraphy (99mTc-sestamibi):
  • Type 1: increased MIBI uptake; Type 2: reduced/absent; Mixed: intermediate
  • Small validation study (n=20); widely available; promising
• RAI and 99mTcO4⁻: suppressed in both types due to iodine load — NOT discriminatory
• Beta-glucuronidase: elevated in Type 2/subacute thyroiditis vs Type 1 — not yet standard practice
• IL-6, CRP: conflicting evidence; limited clinical utility
• sources/amiodarone-thyroid-jcem-2021, rating: high

Thyroidectomy

• Indications (ETA 2018 guidelines):
  1. Progressive cardiac deterioration or reduced LVEF with elevated mortality risk
  2. Severe underlying cardiac disease (e.g., ARVD) or malignant arrhythmias
  3. Unresponsive to aggressive combined medical therapy
• Applicable to all AIT types (Type 1, Type 2, Mixed) as emergency rescue
• Capellani et al. (n=207 retrospective): surgery associated with lower 5- and 10-year overall and cardiac-specific mortality — benefit confined to moderate-to-severely reduced LVEF subgroup
• Plasma exchange as temporising bridge to normalise thyroid hormones pre-operatively
• Requires multidisciplinary team: endocrinologist, cardiologist, anaesthesiologist, high-volume thyroid surgeon
• sources/amiodarone-thyroid-jcem-2021, rating: high

Monitoring Schedule and Post-Discontinuation

• Thyroid function: check before starting amiodarone, then every 3 months during treatment
• Continue ≥1 year after amiodarone withdrawal (half-life ~100 days; drug accumulates in adipose tissue/muscle)
• Late onset AIT post-withdrawal: 7% cases up to 7–16 months after stopping
• sources/amiodarone-thyroid-jcem-2021, rating: high

Anticoagulation Interactions in AITD

• Thyrotoxicosis + warfarin: thyrotoxicosis ↑ catabolism of vitamin K-dependent clotting factors → enhanced warfarin effect → bleeding risk
• Amiodarone + warfarin: amiodarone inhibits CYP2C9/3A4 → ↓ warfarin clearance → ↑ INR and prothrombin time — adjust warfarin dose by 30–50%
• Amiodarone + DOACs (rivaroxaban, apixaban): amiodarone is a CYP3A4/P-gp inhibitor → elevated DOAC plasma levels → increased bleeding risk
• All three interactions can co-exist simultaneously in an AIT patient on OAC → careful monitoring essential
• sources/amiodarone-thyroid-jcem-2021, rating: high; sources/amiodarone-cvdrug-2020, rating: high

Contradictions / Open Questions

• Amiodarone continuation in AIT — no consensus: ETA 2018 recommends continuation for life-threatening arrhythmias; however whether continuation delays Type 2 resolution remains contested (one pilot study suggests it does). For Type 1, continuation perpetuates the iodine overload. Decision requires individualised cardiac risk stratification by cardiologist and endocrinologist jointly. (sources/amiodarone-thyroid-jcem-2021)
• Recombinant TSH for RAI in Type 1 AIT: Proposed to overcome low RAI uptake by stimulating thyroid — not recommended by ETA/ATA guidelines due to risk of worsening thyrotoxicosis. RAI remains impractical short-term in any AIT. (sources/amiodarone-thyroid-jcem-2021)
• Mixed type diagnosis by exclusion: No single test accurately distinguishes Type 2 from mixed type 1/2 AIT. In clinical practice the diagnosis of "mixed" is often made retrospectively after one monotherapy fails. In haemodynamically unstable patients this creates a dilemma — empirical dual therapy (methimazole + prednisone) is reasonable but adds drug burden and risk. (sources/amiodarone-thyroid-jcem-2021)
• Combined IV + oral glucocorticoids for poorly responsive Type 2 AIT: Campi protocol (pulsed IV methylprednisolone + oral prednisone) reported successful in only 4 patients; IV glucocorticoids not clearly superior to oral in a separate n=3 exploratory study. No RCT exists. (sources/amiodarone-thyroid-jcem-2021)

Connections

• Related to entities/Amiodarone — causative drug; all pharmacokinetics and indications
• Related to entities/Dronedarone — non-iodinated amiodarone analogue; does NOT cause thyroid dysfunction
• Related to concepts/Drug-Induced-Arrhythmia — thyrotoxicosis can worsen/precipitate ventricular arrhythmias
• Related to entities/Anderson-Fabry-Disease — amiodarone contraindicated in AFD; thyroid toxicity avoided by using alternative AADs
• Related to concepts/Electrical-Storm — AIT can precipitate electrical storm/VT storm (as in the case)
• Related to concepts/LQTS-Pregnancy-Management — amiodarone contraindicated in pregnancy; thyroid effects also harm the neonate

Sources

• sources/amiodarone-cvdrug-2020
• sources/amiodarone-thyroid-jcem-2021